Skip to main content

Table 3 Study characteristics

From: Quality of life and physical activity in long-term (≥5 years post-diagnosis) colorectal cancer survivors - systematic review

First author year (ref.) country Study design Sample size Age at survey Time since diagnosisa Cancer treatment Cancer stage PA instrument QOL instrument Meeting ACS PA guideline
Blanchard 2004 [35]
USA
Cross-sectional, population-based 86 Mean(SD)
69.22(12.5)
≥2 years 33.7%
≥5 years 30.2%
≥10 years 36.0%
Surgery
Radiation
Chemotherapy
I-IV Adherence to ACS PA
guideline
SF-36 69.8%
Blanchard 2008 [30]b
USA
Cross-sectional, population-based 1918 Mean(SD)
70.2(11.0)
≥2 years 33.4%
≥5 years 35.3%
≥10 years 31.3%
Surgery
Radiation
Chemotherapy
Hormone therapy
Immuno therapy
BMT
I-IV GLTEQ SF-36 35%
Blanchard 2010 [31]b
USA
Cross-sectional, population-based 668 Mean(SD)
70.2(11.1)
≥2 years 26.8%
≥5 years 40.5%
≥10 years 32.0%
In treatment (not further specified) I-IV GLTEQ SF-36 HW 20.0%
OW 30.0%
OB 24.4%
Chambers 2012 [38]
Australia
Cross-sectional & longitudinal, population-based 632 Mean
69.02
≥5 years
Mean(SD)
5(6.1)
Surgery
Chemotherapy
I-III AAS FACT-C
SWLS
Husson 2015 [34]c
The Netherlands
Cross-sectional & longitudinal, population-based 1739 Mean(SD)
68.4(9.4)
≥2 years
Mean(SD)
5.1(2.8)
Radiation
Chemotherapy
I-IV EPIC EORTC QLQ-C30 82%
Mols 2015 [9]c
The Netherlands
Cross-sectional, population-based 1648 Mean(SD)
Chemotherapy: 66.7(9.8)
No chemotherapy: 70.6(9.0)
1–11 years
Mean(SD)
Chemotherapy: 5.6(2.8)
No chemotherapy: 6.1(2.8)
Surgery
Radiation
I-IV EPIC EORTC QLQ-C30
CIPN20
Chemotherapy: 93%
No Chemotherapy: 89%
Rodriguez 2015 [36]
USA
Cross-sectional, population-based 593 Mean 73.8 Only ≥5 years
Mean
6.2
Number of treatments I-III GLTEQ PROMIS
EQ-5D
Thraen-Borowski
2013 [37]
USA
Cross-sectional, population-based 832 Mean(SD) 81.5(5.8) Only ≥5 years
Mean(SD)
8.2(1.7)
CHAMPS SF-36 52%
Van Roekel 2015 [32]d
The Netherlands
Cross-sectional, mono-centric 151 Mean(SD) 69.8(8.7) 2–10 years
Mean(SD)
5.7(1.8)
Surgery
Radiation
Chemotherapy
I-III SQUASH EORTC QLQ-C30
WHODAS II
CIS
HADS
71%
Van Roekel 2016 [33]d
The Netherlands
Cross-sectional, mono-centric 145 Mean(SD) 70.0(8.7) 2–10 years
Mean(SD)
5.7(1.9)
Surgery
Radiation
Chemotherapy
I-III MMOXX1 EORTC QLQ-C30
WHODAS II
CIS
HADS
  1. Ref. Reference, PA physical activity, QOL quality of life, ACS PA guideline American Cancer Society physical activity recommendations of at least 150 min of MVPA per week, SF-36 The Short Form Health Survey, BMT Bone marrow transplantation, GLTEQ Godin Leisure-Time Exercise Questionnaire, HW healty weight, OW over weight, OB obese, AAS The Active Australian Survey, FACT-C Functional Assessment of Cancer Therapy-General (FACT-G) plus CRC-specific measurements, SWLS Satisfaction With Life Scale, EPIC European Prospective Investigation into Cancer Physical Activity Questionnaire, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire, CIPN20 European Organization for Research and Treatment of Cancer QLQ-CIPN20 Chemotherapy-induced peripheral neuropathy questionnaire PROMIS Patient-Reported Outcomes Measurement Information System, EQ-5D EuroQol Five-Dimension Questionnaire, CHAMPS The Community Healthy Activities Model Program for Seniors, SQUASH The Short Questionnaire to Assess Health-enhancing physical activity, WHODAS World Health Organization Disability Assessment Schedule, CIS Checklist Individual Strength, HADS Hospital Anxiety and Depression Scale, MMOXX1 Triaxial MOX activity monitor, aTime since diagnosis at time point of QOL assessment; bArticles based on same study population: American Cancer Society’s Study of Cancer Survivors-II (SCS-II); cArticles based on same study population: All patients diagnosed between 2000 and 2009 and registered in the Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES registry); dArticles based on same study population: Energy for life after ColoRectal cancer (EnCoRe)